Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension

NCT01741194 is registered in ClinicalTrials.gov with Cerecin as lead sponsor.

NCT NCT01741194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01741194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Lead sponsor
Cerecin
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2013
Completion date
April 14, 2017
Enrollment
418 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease